Aderis Pharmaceuticals
Founded Year
1994Stage
Series D | AliveTotal Raised
$58.8MLast Raised
$45M | 22 yrs agoAbout Aderis Pharmaceuticals
Aderis Pharmaceuticals, formerly Discovery Therapeutics, develops and commercializes small molecule, receptor-specific therapeutics for the treatment of central nervous system, cardiovascular and renal diseases.
Missing: Aderis Pharmaceuticals's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Aderis Pharmaceuticals's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Aderis Pharmaceuticals
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Aderis Pharmaceuticals is included in 1 Expert Collection, including Biopharma Tech.
Biopharma Tech
1,568 items
Aderis Pharmaceuticals Frequently Asked Questions (FAQ)
When was Aderis Pharmaceuticals founded?
Aderis Pharmaceuticals was founded in 1994.
Where is Aderis Pharmaceuticals's headquarters?
Aderis Pharmaceuticals's headquarters is located at 85 Main Street, Hopkinton.
What is Aderis Pharmaceuticals's latest funding round?
Aderis Pharmaceuticals's latest funding round is Series D.
How much did Aderis Pharmaceuticals raise?
Aderis Pharmaceuticals raised a total of $58.8M.
Who are the investors of Aderis Pharmaceuticals?
Investors of Aderis Pharmaceuticals include Sanderling Ventures, SV Health Investors, CDIB Capital Group, Palladin Group, Neomed Management and 7 more.
Who are Aderis Pharmaceuticals's competitors?
Competitors of Aderis Pharmaceuticals include Evotec SE, Aquinox Pharmaceuticals, Endocare, Metabolic Solutions Development, Rhythm Pharmaceuticals, Vitae Pharmaceuticals, Anacor Pharmaceuticals, Novira Therapeutics, Icagen (acquired by XRpro Sciences), Cerenis Therapeutics and 23 more.
Compare Aderis Pharmaceuticals to Competitors
Inagen was formed in 2007 to develop therapies for viral diseases. The company's primary candidate is treatment for Cytomegalovirus (CMV). There is a great unmet need for effective treatment to eradicate this serious disease.
NeuroMolecular Pharmaceuticals is developing and commercializing superior neuroprotective medicines for the treatment of central nervous system (CNS) disorders. The Company has built a robust pipeline of neuropsychiatric products based upon its scientists' unique understanding of glutamate's central role in mediating CNS disorders. NeuroMolecular is rapidly advancing its next-generation medicines into clinical studies, with preclinical programs underway in depression, pain, Alzheimer's disease, Parkinson's disease, multiple sclerosis and epilepsy. NeuroMolecular is initially focusing on the development of superior derivatives and dosage formulations of memantine, a drug recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer's disease.
Ascent Therapeutics is a biopharmaceutical company developing a approach to the treatment of human disease that rapidly generates pharmaceuticals critical to many disease processes.
JADO aims to become the leader in the emerging field of Raft intervention therapeutics, through the development of pharmaceutical products with potential for treating a range of human diseases. RAFTs are sub-compartments of cell membranes that play an integral role in key biological pathways. Using its drug development platform, called Raft Intervention Technology, JADO is exploiting new insights and understanding of cell membrane chemistry and organization that aims to enable us to address difficult to treat diseases, such as allergies (atopic dermatitis, asthma), viral and bacterial infections, cancer, neurodegenerative diseases (Alzheimer's) and metabolic illnesses (diabetes, lipid storage diseases).
Marval Biosciences is an early stage company, developing contrast agents for use in X-ray and Computed Tomography (CT) Imaging. Marval's lead candidate, NCTX, targets cardiovascular imaging.
Q Therapeutics, Inc. is developing glial cell-based therapeutic products for central nervous system disorders in which a disease or injury inhibits normal myelin growth and enzyme performance.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.